JP7217273B6 - ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用 - Google Patents

ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用 Download PDF

Info

Publication number
JP7217273B6
JP7217273B6 JP2020523445A JP2020523445A JP7217273B6 JP 7217273 B6 JP7217273 B6 JP 7217273B6 JP 2020523445 A JP2020523445 A JP 2020523445A JP 2020523445 A JP2020523445 A JP 2020523445A JP 7217273 B6 JP7217273 B6 JP 7217273B6
Authority
JP
Japan
Prior art keywords
methoxy
group
mmol
pyridin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500390A (ja
JP7217273B2 (ja
JP2021500390A5 (https=
Inventor
ティエリー・ブイスー
ディルク・ゴッチュリング
ニクラス・ハイネ
ラナ・ルイーズ・スミス・キーナン
マイケル・ディ・ロウ
ホセイン・ラザビ
クリストファー・ロナルド・サーコ
シモン・シュープレナン
秀典 高橋
マイケル・ロバート・ターナー
シンユエン・ウー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hydra Biosciences LLC
Original Assignee
Hydra Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences LLC filed Critical Hydra Biosciences LLC
Priority to JP2020170563A priority Critical patent/JP6979502B2/ja
Publication of JP2021500390A publication Critical patent/JP2021500390A/ja
Publication of JP2021500390A5 publication Critical patent/JP2021500390A5/ja
Publication of JP7217273B2 publication Critical patent/JP7217273B2/ja
Application granted granted Critical
Publication of JP7217273B6 publication Critical patent/JP7217273B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020523445A 2017-10-27 2018-10-25 ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用 Active JP7217273B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020170563A JP6979502B2 (ja) 2017-10-27 2020-10-08 ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762577883P 2017-10-27 2017-10-27
US62/577,883 2017-10-27
US201862628313P 2018-02-09 2018-02-09
US62/628,313 2018-02-09
PCT/EP2018/079276 WO2019081637A1 (en) 2017-10-27 2018-10-25 CARBONYL PYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USES AS TRPC6 INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020170563A Division JP6979502B2 (ja) 2017-10-27 2020-10-08 ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用

Publications (4)

Publication Number Publication Date
JP2021500390A JP2021500390A (ja) 2021-01-07
JP2021500390A5 JP2021500390A5 (https=) 2021-12-02
JP7217273B2 JP7217273B2 (ja) 2023-02-02
JP7217273B6 true JP7217273B6 (ja) 2024-02-08

Family

ID=64270818

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020523445A Active JP7217273B6 (ja) 2017-10-27 2018-10-25 ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用
JP2020170563A Active JP6979502B2 (ja) 2017-10-27 2020-10-08 ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020170563A Active JP6979502B2 (ja) 2017-10-27 2020-10-08 ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用

Country Status (30)

Country Link
US (4) US10889568B2 (https=)
EP (2) EP3700902B8 (https=)
JP (2) JP7217273B6 (https=)
KR (2) KR20200125758A (https=)
CN (1) CN111527078B (https=)
AU (2) AU2018355743B2 (https=)
CA (1) CA3078769A1 (https=)
CL (2) CL2020001097A1 (https=)
CY (2) CY1125488T1 (https=)
DK (2) DK3700902T3 (https=)
ES (2) ES2924933T3 (https=)
FI (1) FI3700902T3 (https=)
HR (2) HRP20220991T1 (https=)
HU (2) HUE059450T2 (https=)
IL (2) IL274039B (https=)
LT (2) LT3700902T (https=)
MX (1) MX387232B (https=)
MY (1) MY202126A (https=)
PE (1) PE20210154A1 (https=)
PH (1) PH12020550503A1 (https=)
PL (2) PL3700902T3 (https=)
PT (2) PT3700902T (https=)
RS (2) RS63535B1 (https=)
SA (1) SA520411843B1 (https=)
SG (2) SG10202011632RA (https=)
SI (2) SI3786160T1 (https=)
TW (2) TWI780246B (https=)
UA (1) UA128474C2 (https=)
WO (1) WO2019081637A1 (https=)
ZA (1) ZA202002372B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202011632RA (en) * 2017-10-27 2021-01-28 Boehringer Ingelheim Int Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
JP7291711B2 (ja) * 2018-02-15 2023-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｒｐｃ６阻害剤
CN111868055B (zh) * 2018-02-16 2024-03-08 勃林格殷格翰国际有限公司 Trpc6的抑制剂
IL315313A (en) * 2018-08-24 2024-10-01 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
JP7585227B2 (ja) * 2019-04-12 2024-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｒｐｃ６阻害剤
JP7594274B2 (ja) 2019-10-24 2024-12-04 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物
WO2021160625A1 (en) 2020-02-11 2021-08-19 Klinikum Rechts Der Isar Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices
AR121846A1 (es) 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
JP7502462B2 (ja) * 2020-04-16 2024-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器状態を処置するためのｔｒｐｃ６阻害剤
CN113105318B (zh) * 2021-02-23 2022-05-20 中山大学 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用
AU2022366192A1 (en) 2021-10-15 2024-02-29 Boehringer Ingelheim International Gmbh Trpc6 inhibitory compounds for treating sepsis
JP2025023360A (ja) * 2021-12-06 2025-02-17 国立大学法人 熊本大学 Ｔｒｐｃ６の発現を抑制する方法
CN121729232A (zh) 2023-08-18 2026-03-24 勃林格殷格翰国际有限公司 用于治疗局灶节段性肾小球硬化症的trpc6抑制剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540594A (ja) 2005-05-19 2008-11-20 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換されたスピロ化合物及び医薬の製造へのその使用
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
WO2016138114A1 (en) 2015-02-25 2016-09-01 Genentech, Inc. Therapeutic pyridazine compounds and uses thereof
JP2021513984A (ja) 2018-02-15 2021-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｒｐｃ６阻害剤
JP2021513966A (ja) 2018-02-16 2021-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｒｐｃ６の阻害剤
JP6979502B2 (ja) 2017-10-27 2021-12-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
WO1993000313A2 (en) 1991-06-27 1993-01-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
AU673569B2 (en) 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
ES2300151T3 (es) 1998-09-22 2008-06-01 Astellas Pharma Inc. Derivados de cianofenilo.
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
JP2004525071A (ja) 2000-07-20 2004-08-19 ニューロジェン コーポレイション カプサイシン受容体リガンド
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
KR20040010713A (ko) 2001-06-15 2004-01-31 야마노우치세이야쿠 가부시키가이샤 페닐피리딘 카보닐 피페라진 유도체
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
DE10222291A1 (de) 2002-05-18 2003-11-27 Schlafhorst & Co W Faserbandzuführeinrichtung
CN1150176C (zh) 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
AU2005296124A1 (en) 2004-10-13 2006-04-27 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
DOP2006000234A (es) 2005-10-28 2007-05-31 Lilly Co Eli Inhibidores de cinasa
JP2009521448A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
JP5019768B2 (ja) 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
PE20090188A1 (es) 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
JP5082538B2 (ja) 2007-03-28 2012-11-28 Ｄｉｃ株式会社 ピペラジン化合物
JP2012512877A (ja) 2008-12-18 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング セロトニン５−ｈｔ２ｂ受容体阻害剤
US20100234603A1 (en) 2009-03-13 2010-09-16 Xin Linghu Process for Making Substituted Aryl Sulfone Intermediates
US20110039850A1 (en) 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
CN102686579A (zh) 2009-10-09 2012-09-19 Irm责任有限公司 作为gpr119活性调节剂的化合物和组合物
CA2781210A1 (en) 2009-11-18 2011-05-26 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
MX2012010115A (es) 2010-03-01 2013-02-26 Gtx Inc Compuestos para el tratamiento de cancer.
TWI525090B (zh) 2010-04-27 2016-03-11 Mitsubishi Tanabe Pharma Corp Novel amide derivatives and their use as pharmaceuticals
MA34300B1 (fr) 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
JP5800786B2 (ja) 2011-10-26 2015-10-28 田辺三菱製薬株式会社 新規アミド誘導体を有効成分として含有する医薬組成物
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN103360343B (zh) 2012-03-30 2017-04-19 凯惠药业(上海)有限公司 一种哌嗪酰胺类化合物的制备方法
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
JP6581970B2 (ja) 2013-05-27 2019-09-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
CA2934700A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
WO2017066705A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
CN107176927B (zh) 2016-03-12 2020-02-18 福建金乐医药科技有限公司 组蛋白去甲基化酶lsd1抑制剂
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
JP2019526617A (ja) 2016-06-20 2019-09-19 ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー 治療用化合物
CN107540636A (zh) 2016-06-29 2018-01-05 成都贝斯凯瑞生物科技有限公司 一种含氮杂环衍生物及其应用
CN106317050B (zh) * 2016-08-24 2018-11-23 烟台大学 一种苯基噻唑衍生物及其制备方法与应用
WO2018159827A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製
WO2018170225A1 (en) 2017-03-15 2018-09-20 Athenex, Inc. Biaryl piperidine amide compounds and methods of use thereof
MA50906A (fr) * 2017-11-16 2020-09-23 Principia Biopharma Inc Inhibiteurs d'immunoprotéasome

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540594A (ja) 2005-05-19 2008-11-20 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換されたスピロ化合物及び医薬の製造へのその使用
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
WO2016138114A1 (en) 2015-02-25 2016-09-01 Genentech, Inc. Therapeutic pyridazine compounds and uses thereof
JP6979502B2 (ja) 2017-10-27 2021-12-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用
JP2021513984A (ja) 2018-02-15 2021-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｒｐｃ６阻害剤
JP2021513966A (ja) 2018-02-16 2021-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｒｐｃ６の阻害剤

Also Published As

Publication number Publication date
AU2018355743A1 (en) 2020-05-14
US20190169168A1 (en) 2019-06-06
CY1125488T1 (el) 2026-02-25
DK3786160T3 (da) 2022-08-22
JP2021500390A (ja) 2021-01-07
EP3700902B1 (en) 2023-03-08
EP3700902A1 (en) 2020-09-02
JP2021008503A (ja) 2021-01-28
WO2019081637A1 (en) 2019-05-02
ES2924933T3 (es) 2022-10-11
EP3786160A1 (en) 2021-03-03
TW202120494A (zh) 2021-06-01
SA520411843B1 (ar) 2024-01-27
SI3700902T1 (sl) 2023-10-30
PT3786160T (pt) 2022-08-19
LT3700902T (lt) 2023-06-26
LT3786160T (lt) 2022-09-26
IL277493B (en) 2022-02-01
CY1126109T1 (el) 2023-11-15
TWI780511B (zh) 2022-10-11
US20210163449A1 (en) 2021-06-03
TW201930294A (zh) 2019-08-01
EP3700902B8 (en) 2023-08-02
FI3700902T3 (fi) 2023-05-25
PE20210154A1 (es) 2021-01-26
HUE059450T2 (hu) 2022-11-28
JP7217273B2 (ja) 2023-02-02
NZ763816A (en) 2025-10-31
PL3786160T3 (pl) 2022-10-24
CL2020002562A1 (es) 2021-01-15
KR20200095467A (ko) 2020-08-10
AU2020250185B2 (en) 2022-04-14
IL274039B (en) 2021-08-31
CA3078769A1 (en) 2019-05-02
ES2946274T3 (es) 2023-07-14
SI3786160T1 (sl) 2022-11-30
MY202126A (en) 2024-04-05
PT3700902T (pt) 2023-05-30
AU2020250185A1 (en) 2020-11-12
IL277493A (en) 2020-11-30
BR112020007818A2 (pt) 2020-10-20
DK3700902T3 (en) 2023-05-22
RS63535B1 (sr) 2022-09-30
PL3700902T3 (pl) 2023-09-04
CN111527078B (zh) 2023-06-02
MX387232B (es) 2025-03-18
SG11202003367TA (en) 2020-05-28
US10800757B2 (en) 2020-10-13
IL274039A (en) 2020-06-30
UA128474C2 (uk) 2024-07-24
US10889568B2 (en) 2021-01-12
HUE062460T2 (hu) 2023-11-28
KR20200125758A (ko) 2020-11-04
HRP20220991T1 (hr) 2022-11-11
CL2020001097A1 (es) 2020-08-28
MX2020004283A (es) 2021-10-21
JP6979502B2 (ja) 2021-12-15
US20190169167A1 (en) 2019-06-06
CN111527078A (zh) 2020-08-11
USRE49699E1 (en) 2023-10-17
PH12020550503A1 (en) 2021-03-22
TWI780246B (zh) 2022-10-11
ZA202002372B (en) 2023-10-25
AU2018355743B2 (en) 2022-04-14
HRP20230502T1 (hr) 2023-09-15
SG10202011632RA (en) 2021-01-28
RS64271B1 (sr) 2023-07-31
KR102724066B1 (ko) 2024-10-30
EP3786160B1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
JP7217273B6 (ja) ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用
JP7291711B2 (ja) Ｔｒｐｃ６阻害剤
CN113677673B (zh) Trpc6的抑制剂
HK40035138B (en) Inhibitors of trpc6
HK40035138A (en) Inhibitors of trpc6
BR112020007818B1 (pt) Compostos derivados de piridina carbonila, sal farmaceuticamente aceitável dos mesmos, composição farmacêutica que os compreende e seu uso como inibidores de trpc6
HK40045092B (en) Pyridine derivatives and therapeutic uses thereof as trpc6 inhibitors
HK40045092A (en) Pyridine derivatives and therapeutic uses thereof as trpc6 inhibitors
EA040737B1 (ru) Пиридинкарбонильные производные и их терапевтические применения в качестве ингибиторов trpc6

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230123

R150 Certificate of patent or registration of utility model

Ref document number: 7217273

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250